Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 755 of 5804
-
Gene therapy aims to bring back light sensitivity in fading eyes
Disease control Recruiting nowA Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
Phase: PHASE1, PHASE2 • Sponsor: Bionic Sight LLC • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for tough lung cancer? trial tests targeted drug against chemo
Disease control TerminatedPrimary Objectives: * Study was designed with multiple primary endpoints analyzed on randomized participants at the time of the cut-off date for each given analysis (progression free survival \[PFS\] and overall survival \[OS\]) * Study success was defined either on PFS or OS * …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo therapy shows promise for Tough-to-Treat head and neck cancer
Disease control CompletedThis is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma. Hypotheses include: * Pembrolizumab + lenvatin…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Breast cancer shot could replace lengthy IV drips
Disease control CompletedThis study will evaluate the pharmacokinetics, efficacy, and safety of the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) as compared with those of the pertuzumab intravenous (IV) and trastuzumab IV formulations in Chinese participan…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can allergy drugs help kids tolerate peanut and more?
Disease control CompletedFood allergy is a serious public health concern that causes potentially-life threatening reactions in affected patients. The prevalence of food allergy in the United States (U.S.) has increased substantially and now affects 15 million patients:4-8% of children (6 million children…
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Malaria vaccine plus bednets: a One-Two punch?
Prevention CompletedThe overall goal of this study is to assess the impact of RTS,S (malaria) vaccination and PBO nets on malaria infection and transmission, independently and how they interact when they are introduced together. The specific objectives for the study are as follows: 1. To estimate …
Sponsor: Michigan State University • Aim: Prevention
Last updated Jun 27, 2026 08:10 UTC
-
Drug cocktail aims to shrink Hard-to-Treat stomach cancers
Disease control CompletedThis is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with pembrolizumab in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who have progressed, or not tolerated, at least one prior line …
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo therapy shows promise in tough lung cancer battle
Disease control CompletedThis study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be stratif…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Could a blood vessel drug reverse sudden blindness in giant cell arteritis?
Disease control CompletedGiant cell arteritis , also named Horton's disease, is the most common vasculitis in subjects over 50 years old. The incidence increases with age : from 188 to 290 cases per million inhabitants per year, with a North-South gradient. The major risk of Horton's disease is blindnes…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to tame rare artery disease
Disease control OngoingThe main objective of this study is to evaluate the efficacy of upadacitinib in combination with a corticosteroid taper regimen compared to placebo in combination with a corticosteroid taper regimen.
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Engineered t cells take on deadly brain cancers
Disease control Recruiting nowIn this study, there are two treatment groups called Cohort 1 and Cohort 2. Cohort 1 is for patients with diffuse midline glioma, diffuse intrinsic pontine glioma, medulloblastoma, or another rare high-grade glioma that expresses GD2. Cohort 2 is for patients with a type of cance…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Blood test could predict clot risk after heart valve surgery
Diagnosis Recruiting nowThis study aims to utilise novel biomarkers assessing thrombosis and thrombolysis (through a blood test), to identify patients undergoing either surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI) who are at risk of thrombosis, and relate th…
Sponsor: East and North Hertfordshire NHS Trust • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
AI could predict who will survive a cardiac arrest
Knowledge-focused Recruiting nowThe overall incidence of cardiorespiratory arrest in Europe is estimated at 350,000 to 700,000 cases per year. Survival rate is estimated at 10.7% for all rhythm disorders combined. Several examples of AI application in the medical field exist. Ting et al have developed a comput…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Supercharged immune cells may make bone marrow transplants safer and more effective
Disease control Recruiting nowGamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who…
Phase: PHASE1 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Desperate measure: rerouting veins to save legs from amputation
Disease control Recruiting nowThe objective of the study is to evaluate early safety and effectiveness of the percutaneous deep foot venous arterialization performed in clinical practice, in an unselected population of patients with "no-option" CLTI.
Sponsor: EndoCore Lab s.r.l. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug could replace chemo for kids with brain tumor
Disease control Recruiting nowThis phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E m…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New combo therapy targets aggressive brain tumors in phase 2 trial
Disease control Recruiting nowThis phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype historically lower grade gliomas or non-histological molecular glioblastomas. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Givin…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Gene-Matched blood transfusions could prevent dangerous antibodies in sickle cell patients
Disease control Recruiting nowTo determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for kids with tough cancers: ponatinib trial launches
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias, lymphomas, and solid tumors.
Phase: PHASE1, PHASE2 • Sponsor: Incyte Biosciences International Sàrl • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Radiation boosts immunotherapy in kidney cancer trial
Disease control OngoingThis trial will evaluate the addition of cytoreductive stereotactic body radiation therapy (SBRT) to standard of care combination ipilimumab and nivolumab (I/N) versus I/N alone for the treatment of metastatic kidney cancer.
Phase: PHASE2 • Sponsor: Ontario Clinical Oncology Group (OCOG) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC